Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

From holes in robotic arm to cracks in the window, astronauts have been complaining about the state of the International Space Station (ISS) for years. A NASA report this week admitted that ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

If all goes well, Sierra Space’s Trash Compaction and Processing System (TCPS) will be operational for ISS astronauts to use by the end of 2026. Humans generate a lot of trash, even when living ...

An International Space Station (ISS) resupply mission in 2026 will send up the Sierra Space trash compactor for testing, company officials stated in a press release on Wednesday (Oct. 16).

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

The leak has been ongoing since 2019 in the Russian segment of the International Space Station (ISS) and was the focus of a new report from NASA's Office of the Inspector General (OIG) published ...

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...

And that's not the only cause for concern, as the space agency has warned that the ISS is at risk of being pelted with micro-meteors and space debris. The air leak is located in the Russian ...

Speculation has been growing over leaks on the International Space Station (ISS), with reports in the media suggesting that NASA astronauts may have to evacuate or face dire consequences.

Under the deal terms, Merck will supply KEYTRUDA for the ongoing, Exelixis-sponsored phase 3 STELLAR-305 pivotal trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC.